Mainstream

Neuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPO

Neuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPO

Post ContentlbrxRead More

You might also be interested in reading Bitcoin: The Worst Quarter Since 2018, But Whales are Still Buying.

September 9, 2025
In Mainstream